Lambert J-C, Luedecking-Zimmer E, Merrot S, Hayes A, Thaker U, Desai P, Houzet A, Hermant X, Cottel D, Pritchard A, Iwatsubo T, Pasquier F, Frigard B, Conneally P M, Chartier-Harlin M-C, DeKosky S T, Lendon C, Mann D, Kamboh M I, Amouyel P
Unité INSERM 508, Institut Pasteur de Lille, BP 245, 1 rue du Professeur Calmette, 59019 Lille Cédex, France.
J Med Genet. 2003 Jun;40(6):424-30. doi: 10.1136/jmg.40.6.424.
Although possession of the epsilon 4 allele of the apolipoprotein E gene appears to be an important biological marker for Alzheimer's disease (AD) susceptibility, strong evidence indicates that at least one additional risk gene exists on chromosome 12. Here, we describe an association of the 3'-UTR +1073 C/T polymorphism of the OLR1 (oxidised LDL receptor 1) on chromosome 12 with AD in French sporadic (589 cases and 663 controls) and American familial (230 affected sibs and 143 unaffected sibs) populations. The age and sex adjusted odds ratio between the CC+CT genotypes versus the TT genotypes was 1.56 (p=0.001) in the French sample and 1.92 (p=0.02) in the American sample. Furthermore, we have discovered a new T/A polymorphism two bases upstream of the +1073 C/T polymorphism. This +1071 T/A polymorphism was not associated with the disease, although it may weakly modulate the impact of the +1073 C/T polymorphism. Using 3'-UTR sequence probes, we have observed specific DNA protein binding with nuclear proteins from lymphocyte, astrocytoma, and neuroblastoma cell lines, but not from the microglia cell line. This binding was modified by both the +1071 T/A and +1073 C/T polymorphisms. In addition, a trend was observed between the presence or absence of the +1073 C allele and the level of astrocytic activation in the brain of AD cases. However, Abeta(40), Abeta(42), Abeta total, and Tau loads or the level of microglial cell activation were not modulated by the 3'-UTR OLR1 polymorphisms. Finally, we assessed the impact of these polymorphisms on the level of OLR1 expression in lymphocytes from AD cases compared with controls. The OLR1 expression was significantly lower in AD cases bearing the CC and CT genotypes compared with controls with the same genotypes. In conclusion, our data suggest that genetic variation in the OLR1 gene may modify the risk of AD.
尽管载脂蛋白E基因的ε4等位基因似乎是阿尔茨海默病(AD)易感性的一个重要生物学标志物,但有力证据表明12号染色体上至少还存在一个风险基因。在此,我们描述了12号染色体上OLR1(氧化型低密度脂蛋白受体1)的3'-UTR +1073 C/T多态性与法国散发性(589例病例和663例对照)和美国家族性(230例患病同胞和143例未患病同胞)人群中AD的关联。在法国样本中,CC + CT基因型与TT基因型相比,经年龄和性别调整后的优势比为1.56(p = 0.001),在美国样本中为1.92(p = 0.02)。此外,我们在+1073 C/T多态性上游两个碱基处发现了一个新的T/A多态性。尽管+1071 T/A多态性可能会微弱调节+1073 C/T多态性的影响,但它与疾病无关。使用3'-UTR序列探针,我们观察到淋巴细胞、星形细胞瘤和神经母细胞瘤细胞系的核蛋白与特定DNA有蛋白结合,但小胶质细胞系没有。这种结合因+1071 T/A和+1073 C/T多态性而改变。此外,在AD病例大脑中,观察到+1073 C等位基因的有无与星形细胞激活水平之间存在一种趋势。然而,β淀粉样蛋白(Aβ)40、Aβ42、总Aβ和Tau负荷或小胶质细胞激活水平不受3'-UTR OLR1多态性的调节。最后,我们评估了这些多态性对AD病例与对照淋巴细胞中OLR1表达水平的影响。与具有相同基因型的对照相比,携带CC和CT基因型的AD病例中OLR1表达显著降低。总之,我们的数据表明OLR1基因的遗传变异可能会改变AD的风险。